1. Scrip
  2. >>R&D
  3. >>Clinical Trials

TauRx To File First Tau-Targeting Drug For Alzheimer’s Following Additional Pivotal Data

 
• By Ayisha Sharma

After previous late-stage setbacks, the Singaporean firm TauRx’s tau aggregation inhibitor asset has succeeded in a pivotal Alzheimer’s disease trial with promising new biomarker data sparking plans for regulatory filings in the US and UK.  

3d rendered medically accurate illustration of a damaged nerve cell
NFL Is A Biomarker Of Neuronal Damage • Source: Shutterstock
Key Takeaways:

  • New data showed HMTM reduced blood concentration of neurofilament light chain by 93%.

TauRx Therapeutics Ltd. is planning to file its anti-tau drug candidate, hydromethylthionine mesylate (HMTM), for the treatment of Alzheimer’s disease following data from the Phase III LUCIDITY trial amidst a broader positive change in direction for the novel approach.

HMTM is a second-generation inhibitor of tau protein aggregation – a key driver of Alzheimer’s – designed to block the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

Deal Build-Up Amid Early ‘Deep’ Response For IGI’s Trispecific In Myeloma

 
• By Anju Ghangurde

IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?

Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

 
• By Sushmita Panda

Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.